

1 ***Brucella abortus* depends on L-serine biosynthesis for intracellular**  
2 **proliferation**

3  
4 **Virginia Révora<sup>1</sup>, María Inés Marchesini<sup>1,\*</sup> and Diego J. Comerci<sup>1,2,\*</sup>**

5 <sup>1</sup>Instituto de Investigaciones Biotecnológicas “Dr. Rodolfo A. Ugalde”, IIB-UNSAM-  
6 CONICET, Universidad Nacional de San Martín, San Martín, Buenos Aires, Argentina

7 <sup>2</sup>Comisión Nacional de Energía Atómica, Grupo Pecuario, Centro Atómico Ezeiza, Buenos  
8 Aires, Argentina.

9  
10 **Running title:** L-serine biosynthesis and *Brucella* virulence.

11  
12  
13 \* Corresponding authors at Instituto de Investigaciones Biotecnológicas *Dr. Rodolfo A.*  
14 *Ugalde*, IIB-UNSAM-CONICET. Universidad Nacional de San Martín. Avenida 25 de  
15 Mayo y Francia, Campus Miguelete, UNSAM, San Martín (1650), Buenos Aires,  
16 Argentina.

17 Phone: (54)11-4006-1500 (ext. 2148). Fax: (54)11-4006-1559.

18 E-mail: [dcomerci@iib.unsam.edu.ar](mailto:dcomerci@iib.unsam.edu.ar); [imarchesini@iib.unsam.edu.ar](mailto:imarchesini@iib.unsam.edu.ar).

19  
20  
21  
22

23 **ABSTRACT**

24 L-serine is a non-essential amino acid and a key intermediate in several relevant metabolic  
25 pathways. In bacteria, the major source of L-serine is the phosphorylated pathway, which  
26 comprises three enzymes: D-3-phosphoglycerate dehydrogenase (PGDH; SerA),  
27 phosphoserine amino transferase (PSAT; SerC), and L-phosphoserine phosphatase (PSP;  
28 SerB). *Brucella abortus* genome encodes two PGDHs (SerA-1 and SerA-2), involved the  
29 first step in L-serine biosynthesis, one PSAT and one PSP, responsible for the second and  
30 third steps, respectively. In this study, we demonstrate that the double mutant *serA-1\_serA-*  
31 *2*, and the single mutants *serC* and *serB* are auxotrophic for L-serine. These auxotrophic  
32 mutants can be internalized but are unable to replicate in HeLa cells and in J77A.1  
33 macrophage-like cells. Replication defects of auxotrophic mutants can be reverted by cell  
34 medium supplementation with L-serine at early times post-infection. Additionally, *serB*  
35 mutant is attenuated in the murine intraperitoneal infection model and has an altered lipid  
36 composition, since lack of L-serine abrogates phosphatidylethanolamine synthesis in this  
37 strain. Taken together, these results reveal that limited availability of L-serine within the  
38 host cell impairs proliferation of the auxotrophic strains, highlighting the relevance of this  
39 biosynthetic pathway in *Brucella* pathogenicity.

40

41

42

## 43 INTRODUCTION

44 Bacteria of the genus *Brucella* are alpha-2-Proteobacteria that cause brucellosis, a chronic  
45 infectious disease affecting diverse species of mammals and humans. *Brucella* infection  
46 causes sterility and abortion in animals, and undulating fever and debilitating disorders in  
47 humans. Brucellosis remains endemic in many countries, resulting in serious public health  
48 problems and economic losses worldwide (1).

49 The ability to replicate in a wide range of mammalian cell types, including endothelial  
50 cells, fibroblasts, epithelial cells and microglia is essential to *Brucella* pathogenesis (2).  
51 The pathogen primarily infects and replicates inside phagocytic cells such as macrophages  
52 and dendritic cells, before disseminating to placental trophoblasts, reproductive tract and  
53 the mononuclear phagocyte system, where they persist to establish a chronic infection in  
54 the host (3, 4).

55 After internalization into host cells, *Brucella* resides in a membrane-bound compartment  
56 known as the *Brucella*-containing vacuole (BCV). BCVs traffic along the endocytic and  
57 secretory pathways, allowing the bacterium to evade killing in phagolysosomes and to  
58 replicate in an endoplasmic-reticulum-derived compartment (5, 6). Afterwards, BCVs  
59 mature into compartments with autophagic features which are required for cell-to-cell  
60 spreading (7).

61 To date, efforts to characterize *Brucella* pathogenesis mechanisms have been focused on  
62 “classical” virulence determinants such as the Type IV Secretion System and its effectors  
63 (8–11), lipopolysaccharide (12), cyclic  $\beta$ -1, 2- glucan (13, 14), two component system  
64 BvrS/BvrR (15), autotransporters and adhesins (16), and transcriptional regulators (17, 18).  
65 These virulence factors participate in key aspects of *Brucella* pathogenesis, like host cell  
66 adhesion and internalization, intracellular replication and innate immune evasion (19).

67 Recently, bacterial nutrition and metabolism during infection have emerged as new  
68 research topics in bacterial pathogenesis (20–22). A recent example is illustrated by *B.*  
69 *abortus* glutamate dehydrogenase (GdhZ), which plays an essential role during intracellular  
70 replication, as GdhZ constitutes an entry point into tricarboxylic acid cycle (TCA) for

71 several amino acids. These results emphasize the importance of amino acids as a main  
72 carbon source during *Brucella* intracellular phase (23).

73 Even though it has been widely accepted that BCVs are nutritionally poor (24, 25), their  
74 exact nutrient composition is unknown. About twenty years ago, random scale mutagenesis  
75 allowed identification of attenuated mutants in genes coding for transport and catabolism of  
76 carbohydrates, as well as genes encoding peptides and amino acids transporters, suggesting  
77 that they could be used by the bacterium as sources of carbon and energy during infection  
78 (25–31). Later, proteomics studies demonstrated reduced key metabolic pathways early  
79 after infection, like TCA, pyruvate and pentose phosphate shunt cycles, as well as sugar  
80 uptake systems (32). On the contrary, enzymes involved in catabolism of amino acid and  
81 proteins are increased, suggesting that *Brucella* may obtain precursors for TCA cycle from  
82 amino acids, like glutamate, during early infection. Altogether, these studies emphasize the  
83 ability of *Brucella* to adjust their metabolism to the intracellular conditions encountered at  
84 each stage of the infection process.

85 Contrary to what is described for many intracellular pathogenic bacteria, which have  
86 reduced their genomes after long periods of co-evolution with their hosts (33), bacteria of  
87 the genus *Brucella* are prototrophic for all amino acids (34, 35). Amino acid biosynthesis  
88 has become relevant in *Brucella* virulence after identification of attenuated mutants in  
89 genes coding for enzymes involved in these pathways, suggesting that BCVs are poor in  
90 amino acids (27, 28, 36–38).

91

92 L-Serine biosynthesis is a major anabolic pathway in most organisms. Although commonly  
93 classified as non-essential amino acid, L-serine plays essential roles as a precursor for  
94 glycine, cysteine, tryptophan, phosphatidyl L-serine, sphingolipids, porphyrins, purines,  
95 glyoxalate, and glycine (39). Also, as the precursor to glycine, L-serine is the major source  
96 of one-carbon units that serve as the donors in methylation reactions mediated by  
97 derivatives of tetrahydrofolate and S-adenosyl methionine (40). Conversion of L-serine to  
98 glycine is a reversible reaction catalyzed by serine hydroxy methyl transferase (SHMT E.C.  
99 2.1.2.1) (41). Nonetheless, the major route for L-serine biosynthesis in bacteria is the  
100 phosphorylated pathway (Fig. 1A), which comprises three sequential steps catalyzed by 3-  
101 phosphoglycerate dehydrogenase (PGDH/SerA; EC 1.1.1.95), phosphoserine

102 aminotransferase (PSAT/SerC; EC 2.6.1.52), and phosphoserine phosphatase (PSP/SerB;  
103 EC 3.1.3.3).

104

105 Given its central role in metabolism, we sought to characterize and determine the  
106 importance of L-serine biosynthesis pathway in *B. abortus*. In the present study, three  
107 deletion mutants auxotrophic for L-serine have been obtained and characterized *in vitro* and  
108 *in vivo*. All three auxotrophic mutants failed to replicate intracellularly, and one of them  
109 proved to be attenuated in mice in the acute and chronic phases of the infection. These  
110 results indicate that during intracellular stages, *B. abortus* depends on the biosynthesis of L-  
111 serine via the phosphorylated pathway to sustain its proliferation.

112

113 **MATERIALS AND METHODS**

114 **Bacterial strains, plasmids and growth conditions**

115 Bacterial strains and plasmids used in this study are listed in Supplementary Table S1. *B.*  
116 *abortus* strains were inoculated in tryptic soy agar (TSA) (Difco/Becton Dickinson, Sparks,  
117 MD) or in tryptic soy broth (TSB) at 37°C on a rotary shaker for 16-20 hs. When indicated,  
118 media were supplemented with 50 µg/ml kanamycin, 5 µg/ml nalidixic acid, and/or  
119 50µg/ml ampicillin. All work with live *B. abortus* was performed in a biosafety level 3  
120 laboratory facility. *E. coli* strains were grown in Luria Broth (LB) liquid or solid medium,  
121 at 37°C overnight. Antibiotics, when required, were added at the following concentrations:  
122 50 µg/ml kanamycin or 100 µg/ml ampicillin.

123 **Construction of *B. abortus* mutants and genetic complementation**

124 To obtain the mutant strains by unmarked gene deletion, the regions flanking each gene  
125 (*serA-1*: *bab1\_1697*, *serA-2*: *bab2\_0783*, *serC*: *bab1\_1699* and *serB*: *bab1\_1410*) were  
126 amplified and ligated using recombinant PCR technique (42). The primers used for PCR  
127 amplification of the 500 bp upstream and downstream regions are listed in Supplementary  
128 Table S2. Both PCR fragments obtained were used in an overlapping PCR to obtain a 1000  
129 bp fragment. These fragments were ligated into pK18*mob-sacB* vector (43). The resulting  
130 plasmids were transformed in *Escherichia coli* S17λ*pir*, and subsequently conjugated to *B.*  
131 *abortus* 2308 by biparental mating. Single recombinants were selected with kanamycin  
132 (Km) and replica plated in TSA supplemented with 10% sucrose (Suc). Colonies Km<sup>r</sup> and  
133 Suc<sup>s</sup> were grown ON in TSB without antibiotics and plated on TSA with 10% Suc to  
134 counterselect the double recombinants. Double recombination events (Km<sup>s</sup> Suc<sup>r</sup>) were  
135 selected and gene deletion was confirmed by PCR. To obtain double mutant *serA-1\_serA-2*,  
136 the plasmid pK18*mob-sacB* containing the 1000 pb-flanking region of *serA-2* was  
137 conjugated into *serA1* mutant. Selection of recombination events was performed like in  
138 single mutant constructions.

139 Genetic complementation of the mutant strains was achieved by expression of C-terminal  
140 3xFlag-tagged versions of the proteins SerB, SerC and SerA-2 from plasmid pBBR1-  
141 MCS4-3xFlag (pLF) (44). All genes were amplified by PCR from *B. abortus* 2308 genomic

142 DNA using primers listed in Supplementary Table S3. PCR products were digested with  
143 BamHI and SpeI, and the resulting fragments cloned into the same sites of pLF to generate  
144 in-frame fusions to the 3xFLAG epitope under *lac* promoter control. The resulting  
145 constructions were introduced in the corresponding *B. abortus* mutant strains by biparental  
146 mating. To complement *serA-1\_serA-2* double mutant, the promoter regions and genes  
147 coding for SerA-1 or SerA-2 were amplified by PCR using primers listed in Table 3  
148 (Fw\_SerA-1\_pBBR2\_SpeI/Rv\_SerA-1\_pBBR2\_BamHI and Fw\_SerA-  
149 2\_pBBR2\_SpeI/Rv\_SerA-2\_pBBR2\_BamHI). The PCR products were digested with  
150 BamHI and SpeI, and the fragments were cloned into pBBR1-MCS2. The resulting  
151 plasmids were introduced in *B. abortus* double mutant strain by biparental mating. For  
152 genetic complementation with both genes, pLF\_*serA-2* and pBBR1 MCS2\_*serA-1* were  
153 introduced simultaneously in the double mutant.

#### 154 **Growth curve in TSB and minimal medium**

155 Starter cultures were grown in TSB in a rotary shaker (200 rpm) overnight at 37°C, and  
156 then diluted with the same medium to OD<sub>600</sub>= 0.1 (10 ml cultures in 50 ml flasks). Culture  
157 growth was monitored by measuring the absorbance at 600nm every 4 hours. When  
158 indicated, the medium was supplemented with 10 mM L-serine (Sigma-Aldrich). Bacterial  
159 growth in minimal medium Gerhardt-Wilson (GW) (45) was measured as described above,  
160 except minimal medium was used as the diluting solution of starters cultures grown until  
161 exponential phase (0.6-0.8 OD<sub>600</sub>). Bacterial growth was monitored by measuring OD<sub>600</sub>  
162 every 24 hours. When indicated, 10mM L-serine (Sigma) was added to the growth medium.  
163 Four independent experiments were performed in duplicates.

164

#### 165 **Cell culture infection and replication assays**

166 Log-phase bacteria grown in TSB were used to infect J774A.1 macrophage-like cells at a  
167 multiplicity of infection (MOI) of 50:1, or HeLa cells at MOI 1000:1. Bacteria were  
168 centrifuged onto cells at 400 x g for 10 min to promote bacterium-cell contact. After 60  
169 min, wells were gently washed three times with PBS and incubated for 120 min with fresh  
170 medium containing 50 µg ml<sup>-1</sup> gentamicin and 100 µg ml<sup>-1</sup> streptomycin to kill non-

171 internalized bacteria. Thereafter, antibiotics concentrations were decreased to 10 µg ml<sup>-1</sup>  
172 gentamicin and 20 µg ml<sup>-1</sup> streptomycin. At the indicated times, infected cells were either  
173 washed three times with PBS and lysed with 500 µl of 0.1% Triton X-100 in PBS (Sigma-  
174 Aldrich) for CFU counts or processed for immunofluorescence staining as described below.  
175 Intracellular CFU counts were determined by plating serial dilutions on TSA with the  
176 appropriated antibiotic.

### 177 **Immunofluorescence microscopy and antibodies**

178 HeLa cells were seeded on 12-mm coverslips in 24-well plates at 5x10<sup>4</sup> cells per well. After  
179 24 hs, cells were infected with the indicated *B. abortus* strains and at different times post-  
180 infection, cells were washed three times with PBS and fixed with 4% paraformaldehyde  
181 (pH 7.4) for 15 min at 37°C. Fixed cells were washed again twice and coverslips were  
182 incubated for 30 min in blocking buffer (PBS with 10% horse serum and 0.1% saponin).  
183 Afterwards, coverslips were incubated for 60 min in blocking buffer containing primary  
184 antibodies. After two washes in 0.1% saponin PBS, the coverslips were incubated for 60  
185 min in blocking buffer containing secondary antibodies. Finally, the coverslips were  
186 washed three times in PBS and once in milli Q water and mounted on glass slides using  
187 Fluorsave (Calbiochem). The primary antibodies used were rabbit anti-*Brucella*,  
188 monoclonal mouse anti-*Brucella* (M84), monoclonal mouse anti-human LAMP-1 antibody  
189 (H4A3), monoclonal rat anti-mouse LAMP-1 antibody (1D4B) (Developmental Studies  
190 Hybridoma Bank, National Institute of Child Health and Human Development, University  
191 of Iowa) and anti-human calnexin antibody (Abcam). The secondary antibodies used were  
192 Alexa Fluor goat anti-mouse IgG, goat anti-rat IgG and goat anti-rabbit IgG (Molecular  
193 Probes, Invitrogen). Confocal images were acquired using an IX-81 microscope attached to  
194 a FV-1000 confocal module, with a PLAN APO 60X NA 1.42 oil immersion objective  
195 (Olympus, Japan). The acquisition software used was FV 10-ASW 3.1. Images were treated  
196 using ImageJ 1.45s Software (NIH, USA), and. images of 1024 x 1024 pixels were then  
197 assembled using Adobe Photoshop CS. Bacterial enumeration in HeLa cells and  
198 quantification of LAMP-1 and calnexin colocalization with BCVs were performed on a  
199 Nikon microscope (Eclipse TE 2000) at a magnification of X60 with a lens with a



200 numerical aperture of 1.42. At least 300 bacteria in random fields were analyzed per  
201 sample.

#### 202 **Microsomal and acidic pH susceptibility assay**

203 Microsomes derived from J774A.1 murine macrophages were obtained as described in  
204 (46). Protease activity in this microsomal fractions was determined using a casein-  
205 BODIPY-FL, whose fluorescence is quenched. Protease-catalyzed hydrolysis relieves this  
206 quenching, yielding bright green fluorescent peptides. The increase in fluorescence  
207 emission is proportional to casein digestion and protease activity. Fluorescence was  
208 measured with a fluorescence plate reader (FilterMaxF5 Molecular devices). To determine  
209 the sensitivity of *Brucella* strains to lysosomal killing,  $2.5 \times 10^5$  CFU were incubated with 20  
210  $\mu\text{g}$  of the purified microsomal fractions or buffer (negative control) for eight hours at  $37^\circ\text{C}$ .  
211 After incubation, serial dilutions were plated in TSA to determine the number of viable  
212 bacteria. Susceptibility to low pH was assessed by incubating log-phase bacteria grown in  
213 TSB in phosphate buffer saline (PBS) pH 4 or pH 7 at  $37^\circ\text{C}$  for four hours. Serial dilutions  
214 were plated after incubation to determine the number of viable bacteria after the treatments.

#### 215 **Mice infection**

216 All experimental protocols of this study were approved by the Committee on the Ethics of  
217 Animal Experiments of the University of San Martín (CICUAE UNSAM) and were  
218 conducted in agreement with international ethical standards for animal experimentation  
219 (Guide for the Care and Use of Laboratory Animals of the National Institutes of Health).  
220 Eight-week-old female BALB/c mice were intraperitoneally inoculated with  $5 \times 10^4$  CFU of  
221 *B. abortus* strains in PBS (200  $\mu\text{l}$ ). At 7, 15 and 30 days post inoculation, spleens from  
222 infected mice were removed, weighed, and homogenized in 3 ml of PBS. Spleen  
223 homogenates were serially diluted and plated in TSA for CFU enumeration. During the  
224 experimental protocol, mice were housed in an appropriate biosafety level 3 facility and  
225 handled according to international guidelines required for animal experiments.

226

#### 227 **Thin-layer chromatography lipid analysis**

228 Log-phase bacteria were used to inoculate fresh Gerhardt Wilson medium supplemented  
229 with  
230 100  $\mu$ M of choline dihydrogen citrate (Sigma- Aldrich Co.) at an initial OD<sub>600</sub> of 0.2.  
231 Cultures were grown for 48 hs until they reached an OD<sub>600</sub> of  $\sim$  1 and bacteria were  
232 harvested by centrifugation. Lipids were extracted according to the method of Bligh and  
233 Dyer (47) and separated on silica gel plates (Kieselgel 60; Merck) by using chloroform-  
234 methanol-water (14:6:1 [vol/vol/vol]) as a running solvent. Aminolipids were revealed by  
235 spraying the plate with 0.2% ninhydrin in ethanol and heating at 100 °C for three minutes  
236 (48). Phospholipids were visualized by destructive treatment with a solution 8% H<sub>3</sub>PO<sub>4</sub>:  
237 10% CuSO<sub>4</sub> and charring (49).

238

#### 239 **Statistical Analyses**

240 Statistical analyses were performed with Prism 6 software (GraphPad) with one or two-way  
241 ANOVA and Bonferroni post-test for multiple comparisons to assess statistical differences  
242 between two experimental data sets. *P*-values: ns, not significant; \*, *P*<0.05; \*\*, *P*<0.01;  
243 \*\*\*, *P*<0.001.

244

245 **RESULTS**246 **Generation and characterization of L-serine auxotrophic mutants**

247 In the phosphorylated biosynthetic pathway, L-serine is derived from the glycolytic  
248 intermediate 3-phospho-D-glycerate (PGA), in a three-step reaction (Fig. 1A). The first  
249 enzyme is D-3- phosphoglycerate dehydrogenase (henceforth PGDH) that converts PGA to  
250 phosphohydroxypyruvate (PHP) with the concomitant reduction of NAD<sup>+</sup> to NADH. *B.*  
251 *abortus* genome encodes two isoforms of PGDH/SerA: SerA-1 (BAB1\_1697) and SerA-2  
252 (BAB2\_0783). Both PGDHs are 38% identical and comprise the catalytic domain and a C-  
253 terminal allosteric substrate binding domain (ASB) in SerA-1, or an aspartate kinase–  
254 chorismate mutase–TyrA domain (ACT) at the C-terminus of SerA-2.

255

256 In order to obtain L-serine auxotrophic mutants, genes coding for PGDHs were deleted to  
257 produce single (*serA-1* and *serA-2*) and double (*serA-1\_serA-2*) mutant strains. Unmarked  
258 gene deletion of *serA-1* or *serA-2* had no significant effect on vegetative growth in TSB  
259 (not shown) or in the gluconeogenic medium Gerhardt-Wilson (GW) without L-serine  
260 supplementation (Fig. 1B), demonstrating that the effect of the single mutations can be  
261 compensated by the presence of the second gene that encodes a functional PGDH. On the  
262 contrary, the double mutant *serA-1\_serA-2* required L-serine supplementation for growth in  
263 minimal medium (Fig. 1B), indicating that L-serine biosynthesis is abrogated in this strain.  
264 At this point, it is worth mentioning that 10mM L-serine supplementation to the growth  
265 media TSB or GW does not confer any advantage in vegetative growth to *B. abortus* wild  
266 type 2308 (Fig. S1 A and B). Genetic complementation of the double mutant with plasmids  
267 encoding SerA-1 and/or SerA-2 partially restored wild type growth in minimal medium  
268 without L-serine (Fig. 1C), probably due to plasmids instabilities in these strains. These  
269 results suggest that SerA-1 and SerA-2 are involved in the first step of L-serine  
270 biosynthesis in *B. abortus*.

271 In the following steps, phosphoserine amino transferase (henceforth SerC; BAB1\_1699)  
272 converts PHP to L-phosphoserine (PS) with the concomitant conversion of glutamate to  $\alpha$ -  
273 ketoglutarate, followed by the conversion of PS to L-serine by phosphoserine phosphatase  
274 (henceforth SerB; BAB1\_1410) (Fig. 1A). Unmarked gene deletion of *serC* or *serB* had no

275 significant effect on vegetative growth in TSB (not shown). As expected, these mutants  
276 required exogenous L-serine (10mM) for growth in GW medium (Fig. 1D). The growth  
277 defect of these auxotrophic mutants could be fully rescued by complementation with  
278 plasmids coding for the corresponding enzymes (Fig. 1E).

279 These results indicate that when grown in a gluconeogenic medium such as GW, where the  
280 only carbon and nitrogen sources are glycerol and glutamate, *B. abortus* depends on the  
281 biosynthesis of L-serine for growth. In addition, the ability to rescue the growth defect of  
282 the auxotrophs upon addition of L-serine to the media, suggests that *B. abortus* can  
283 incorporate this amino acid through a transport system not identified yet.

284

#### 285 **L-serine biosynthesis is necessary for *B. abortus* intracellular replication**

286

287 *Brucella* can adhere, invade and proliferate inside different cell types including both  
288 professional and non-professional phagocytic cells. To assess the impact of L-serine  
289 auxotrophy in the intracellular lifestyle of *B. abortus*, we evaluated the intracellular  
290 replication of the wild type S2308, *serA-1\_serA-2*, *serC* or *serB* mutants and the  
291 corresponding complemented strains in HeLa and J774A.1 cell lines, two widely used  
292 infection models of non-professional and professional phagocytic cells. Genetic  
293 complementation of the double mutant with only one of the genes did not fully restore  
294 intracellular replication levels in HeLa and J774A.1 cells (not shown). For this reason,  
295 *serA-1\_serA-2* mutant was complemented with both genes in these experiments. As can be  
296 shown in Fig. 2 (A-F), all mutant strains showed no differences with wild type at 4 hs p.i.,  
297 but failed to replicate in both cell types, with 1 to 4 log-units decrease in CFU counts when  
298 compared to S2308 at 24 hs or 48 hs p.i. Genetic complementation of the mutants with  
299 plasmids encoding the corresponding enzymes restored intracellular replication of the  
300 mutants with the exception of *serC* at 24 hs p.i. in both cell types (Fig. 2 A-F, green bars).  
301 Likewise, addition of 10 mM L-serine to the cell medium RPMI 1640 at the beginning of  
302 the infection process rescued the intracellular growth defect of L-serine auxotrophic  
303 mutants (Fig. 2 A-F, blue bars), but had no effect on intracellular replication of wild type *B.*  
304 *abortus* (Fig S1 C and D). These results demonstrate that *B. abortus* requires biosynthesis  
305 of L-serine to replicate intracellularly, and that exogenous L-serine can be incorporated into

306 the BCVs to rescue the replication defect of the auxotrophs. Since the three auxotrophic  
307 mutants exhibited a similar phenotype in cells, we decided to continue the characterization  
308 only with *serB* mutant in the following experiments.

309

310 In order to further characterize L-serine requirements of intracellular *B. abortus*, host cell  
311 medium was supplemented with the amino acid at 6 hs, 10 hs and 24 hs p.i. Interestingly,  
312 supplementation of cell medium with L-serine can only restore intracellular proliferation of  
313 *serB* mutant in HeLa and J774A.1 macrophage-like cells if added before 24 hs p.i. (Fig. 3 A  
314 and B). These results are in agreement with our previous results demonstrating that *B.*  
315 *abortus* cannot use host cell L-serine to sustain the intracellular replication phase, and  
316 therefore depends on *de novo* biosynthesis. The results also highlight the importance of L-  
317 serine availability during the first stages of infection in order to successfully proliferate  
318 within cells. The fact that supplementation of the cell culture medium with L-serine  
319 resumes the intracellular growth of the mutant, indicates that *B. abortus* is capable of  
320 transporting the amino acid through both the BCV and the bacterium membranes.

321

322 Since intracellular levels of L-serine cannot support proliferation of auxotrophic mutants,  
323 we sought to determine the minimal concentration required to rescue the replication defect  
324 of *serB* by infecting HeLa cells and adding increasing concentrations of L-serine at the  
325 beginning of the *in vitro* infection assay. As can be seen in Fig. 4, there is a minimum  
326 threshold of L-serine concentration capable of rescuing the intracellular replication defect  
327 of *serB*. At least 1.6 mM L-serine needs to be added to the cell medium RPMI 1640  
328 (containing 0.28-0.4 mM L-serine) to bypass *serB* proliferation defect. These results  
329 confirm that *Brucella* can incorporate L-serine through both the bacterial cell envelope and  
330 the BCV membrane to support intracellular replication.

331

### 332 **Abrogation of L-serine biosynthesis impairs biogenesis of replicative vacuoles in** 333 **phagocytic cells**

334 Once internalized, *Brucella* resides within a membrane-bound vacuole, the *Brucella*-  
335 containing vacuole (BCV), which undergoes remodeling from a compartment with  
336 endosomal/lysosomal features into an organelle derived from the host endoplasmic

337 reticulum (ER) that supports bacterial replication (rBCV) (50–53). Given that *B. abortus* L-  
338 serine auxotrophic mutants displayed intracellular replication defects, we investigated the  
339 biogenesis of the rBCV in HeLa cells infected with *serB* mutant. We first quantified  
340 acquisition and exclusion of the endosomal/lysosomal marker LAMP-1 at 4 hs and 24 hs  
341 post-infection, respectively. At 4 hours p.i.  $64.59 \pm 6.06\%$  of wild type BCVs were positive  
342 for LAMP-1, compared to  $67.23 \pm 4.57\%$  for *serB* BCVs. At 24 hs p.i., *serB* BCVs  
343 excluded the lysosomal marker and only  $31.20 \pm 3.65\%$  remained positive for LAMP-1,  
344 compared to  $26.95 \pm 5.16\%$  of wild type BCVs (Suppl Fig. 2A). Addition of 10 mM L-serine  
345 to the cell medium had no effect on LAMP-1 labeling of BCVs at 4 and 24 hours p.i. To  
346 further characterize *serB* intracellular traffic, we quantified acquisition of calnexin, an ER  
347 resident protein. By 24 hs p.i.,  $71.37 \pm 5.13\%$  of wild type BCVs and  $69.95 \pm 4.73\%$  of *serB*  
348 BCVs were positive for calnexin (Suppl. Fig. 2B).

349

350 Detailed inspection and enumeration of intracellular bacteria by immunofluorescence  
351 microscopy of infected HeLa cells at 24 hs p.i., revealed that cells infected with wild type  
352 *B. abortus* show *foci* of intracellular replication containing more than seven bacteria per  
353 cell, whereas no signs of intracellular replication were observed in cells infected with *serB*,  
354 with 98.53% of the cells with none or less than four bacteria (Fig. 5A). At 48 hs p.i., the  
355 cells infected with *serB* remained free of intracellular replication *foci*, with  $88.43 \pm 1.31\%$  of  
356 cells without bacteria and only  $11.25 \pm 1.47\%$  with less than four bacteria (Fig. 5B). As  
357 expected, supplementation of the cell culture medium with 10 mM L-serine restored the  
358 replication defect of the auxotrophic mutant, since  $2.34 \pm 0.04\%$  of cells presented  
359 intracellular *foci* with more than seven bacteria. These results are consistent with the  
360 intracellular replication curves (Fig. 2E) and are illustrated by representative confocal  
361 images of infected HeLa cells at 48 hs p.i. (Fig. 5C). These images show replicative *foci*  
362 found in cells infected with the wild type but barely detectable in those infected with *serB*.  
363 As expected, supplementation with 10 mM L-serine restored the intracellular proliferation  
364 of the mutant as judged by the higher number of replicative *foci* (Fig. 5C). The images also  
365 illustrate calnexin association to BCVs in both strains. Together, these results indicate that  
366 *B. abortus* L-serine auxotrophs are competent to promote the biogenesis of rBCVs in HeLa  
367 cells but are unable to replicate within them.

368 To assess if the same is true in professional phagocytic cells, LAMP-1 acquisition and  
369 exclusion was evaluated in infected J774A.1 macrophages. At 4 hours p.i., 71.31±4.84% of  
370 wild type BCVs were decorated with LAMP-1, compared to 62.468 ±3.49% for *serB*  
371 BCVs. At 24 and 48 hs p.i, wild type BCVs were able to progressively exclude this  
372 lysosomal marker with 30.27±0.39% and 19.5±3.5% of LAMP-1 positive vacuoles,  
373 respectively. On the contrary, *serB* BCVs remained positive for this marker at 24 and 48 hs  
374 p.i. with 51.35±5.63% and 55.50±6.36% of LAMP-1 positive BCVs, respectively (Fig.  
375 6A). Confocal microscopy images illustrate *B. abortus* wild type and *serB* mutant inside  
376 J774A.1 macrophages at 48 hs p.i. (Fig. 6B). In agreement with the intracellular replication  
377 curves (Fig. 2F), *serB* mutant fails to replicate inside these cells and is decorated with  
378 LAMP-1. Additionally, *serB* lysosomal degradation inside these cells is evidenced by small  
379 *puncta* labeled with total anti-*Brucella* antibodies (Fig. 6 B smaller arrowheads). In contrast  
380 to what was observed in non-phagocytic Hela cells, inside a competent phagocytic cell such  
381 as J774.A1 macrophages, *serB* serine auxotroph could not complete the biogenesis of the  
382 rBCV, remaining mostly in LAMP-1 positive and calnexin negative compartments (not  
383 shown) where it was eventually degraded.

384

### 385 **L-serine auxotrophy alters *B. abortus* membrane lipid composition**

386 The *Brucella* cell envelope is composed of phosphatidylethanolamine (PE),  
387 phosphatidylcholine (PC), ornithine lipid (OL), cardiolipin (CL), and phosphatidylglycerol  
388 (PG) (54, 55). In *B. abortus*, PE is synthesized by the phosphatidylserine synthase pathway  
389 (Fig. 7A). The first reaction requires the condensation of L-serine with CDP-diacylglycerol  
390 catalyzed by the Phosphatidylserine synthase (PssA) to produce phosphatidylserine, which  
391 is quickly decarboxylated by the Phosphatidylserine decarboxylase (Psd) to produce PE  
392 (54). In order to assess whether L-serine auxotrophy affects the membrane lipid  
393 composition, *B. abortus* wild type and the *serB* mutant were grown in GW medium  
394 supplemented with choline, and the total lipids were extracted and analyzed by thin layer  
395 chromatography and revealed by acid charring (total lipids) and ninhydrin staining for  
396 aminolipids. As expected, the spot corresponding to PE was absent when the mutant was  
397 grown in a defined medium without L-serine. This defect can be circumvented by



398 supplementing the medium with 10mM L-serine (Fig. 7B). Lack of PE in the cell envelope  
399 was compensated by increasing the amount of OL. These findings indicate that impairment  
400 of L-serine biosynthesis abrogates PE formation, which impacts the lipid membrane  
401 composition suggesting that *B. abortus* L-serine auxotrophs depend on exogenous L-serine  
402 to form PE, one of the major membrane phospholipids.

403

404 Since phospholipid composition in bacterial cell envelope is critical for the interaction with  
405 the host, we analyzed if the lack of PE in *serB* increased its susceptibility to acidic pH  
406 conditions or lysosome killing. First, we evaluated the sensitivity of the bacteria to low pH  
407 conditions by incubating S2308, *serB* and *pssA* mutant strains in PBS pH 4 for four hours.  
408 No differences were detected in the number of viable bacteria recovered after four hours of  
409 incubation in this acidic pH (Suppl Fig. 3A). *pssA* mutant strain was included as a control,  
410 since it cannot synthesize PE, but L-serine biosynthetic pathway remains intact (54).  
411 Additionally, we evaluated if lack of PE synthesis increases *serB* sensitivity to lysosomal  
412 proteolytic activity. To achieve this, microsomal fractions obtained from JJ74A.1  
413 macrophages were incubated with S2308, *serB* and *pssA* mutant strains, and *serB*  
414 complemented mutant. After eight hours of incubation with the microsomal fractions, no  
415 differences in sensitivity to lysosomal proteolytic activity were detected among the strains  
416 (Suppl Fig. 3B). Therefore, the inability of *serB* mutant to proliferate intracellularly,  
417 whether in professional or non-professional phagocytes, is not related to the impaired PE  
418 biosynthesis, but to its failure to produce serine *de novo* and/or to extract it from the host  
419 cell.

420

#### 421 **L-serine biosynthesis is required for full virulence in BALB/c mice**

422 Since auxotrophic mutant strains fail to replicate intracellularly and to produce PE, we  
423 sought to evaluate the virulence of *serB* mutant in the murine infection model. As shown in  
424 Fig. 8, *serB* auxotrophic mutant exhibited significantly reduced levels of splenic  
425 colonization. At 7 days p.i., *serB* mutant showed 2 log units reduction in CFU in  
426 comparison to the wild type. This difference became larger at 15 days p.i., with 2.867 CFU  
427 log unit reduction (Fig. 8). Although statistically significant, the difference in CFU between  
428 wild type and *serB* diminished to 1.641 log CFU at 30 days p.i., indicating that this



429 auxotrophic mutant was able not only to persist in spleen, but also to replicate. Genetic  
430 complementation with a plasmid encoding the fusion protein SerB\_3xFLAG partly restored  
431 virulence in mice. These results can be explained by the instability of certain plasmids in  
432 the mice infection model, where antibiotic selection cannot be achieved. The colonization  
433 defect of *serB* mutant was concomitant with reduced splenomegaly and hepatomegaly,  
434 hallmarks of *Brucella* infection (data not shown). These results indicate that *B. abortus*  
435 requires L-serine biosynthesis to achieve an efficient infection in the mammalian host.  
436  
437

438 **DISCUSSION**

439 L-serine is a non-essential amino acid produced by a biosynthetic pathway in nearly all  
440 organisms (56). In this study, we show that disruption of the genes coding for the enzymes  
441 involved in the anabolic pathway causes L-serine auxotrophy, which impairs the ability of  
442 *B. abortus* to proliferate inside the host cell and affects virulence in the mice infection  
443 model of brucellosis.

444

445 The crucial role of L-serine biosynthesis in pathogenicity is supported by a previous study  
446 describing a transposon-insertion mutant in *B. suis* gene coding for SerB, which displays  
447 an attenuated phenotype after 48 hs of infection in THP-1 macrophages (25). To our  
448 knowledge, attenuated mutants in the genes coding for SerC or SerA have not been  
449 reported nor identified in mutagenesis analyses. In the case of SerA, this can be explained  
450 by the presence of two PGDH isoforms encoded in *B. abortus* genome. Despite the little  
451 identity and different domain architectures of SerA-1 and SerA-2, both enzymes proved to  
452 be functionally redundant. Single mutants were prototrophs for L-serine and only  
453 simultaneous deletion of *serA-1* and *serA-2* produced a growth defect in minimal medium  
454 without L-serine. *B. melitensis* SerA-2 crystallographic structure has been resolved (PDB  
455 entry 3k5p) and it closely resembles *E. coli* PGDH structure (Edwards, T.E. et al.,  
456 unpublished). ACT domain in *E. coli* PGDH is allosterically and cooperatively inhibited by  
457 L-serine to achieve negative feedback regulation of the biosynthetic pathway (57). Further  
458 studies are required in order to characterize the function of ACT and ASB domains of  
459 PGDH isoforms in regulation of the biosynthetic pathway in *B. abortus*.

460

461 Apart from the phosphorylated pathway, L-serine can also be produced from glycine by  
462 SHMT (56). However, as this reaction depletes glycine levels, this is not a major route to  
463 produce L-serine. In fact, this pathway cannot compensate the effect of the mutations  
464 responsible for L-serine auxotrophy. For those reasons, we postulate that *B. abortus* SHMT  
465 encoded by gene locus *babI\_0787* functions *in vivo* not for serine biosynthesis but for  
466 glycine production.

467

468

469 Several amino acid auxotroph strains of bacterial pathogens are often attenuated for  
470 intracellular growth and infection. *Mycobacterium tuberculosis* proline and lysine  
471 auxotrophs (58–60), and *Salmonella* auxotrophs for histidine and methionine (61–63) are  
472 examples of attenuated mutants *in vivo*. In *B. abortus*, L-serine depletion in the mutants  
473 *serA-1\_serA-2*, *serC* and *serB* was likely the cause of intracellular replication defects,  
474 which could be rescued by amino acid supplementation of the host cell medium. The fact  
475 that the mutants were able to transport and use extracellular L-serine from RPMI-  
476 supplemented medium, suggests that wild-type *B. abortus* does not obtain enough L-serine  
477 from the host during infection and must synthesize its own. Delivery of extracellular L-  
478 serine into *B. abortus* cytoplasm requires transport across three membranes: the host cell  
479 membrane, the phagosomal membrane and ultimately the bacterial membranes. Amino acid  
480 supplementation and uptake by intracellular pathogens has already been described in  
481 *Francisella* (64, 65) and *Legionella* (66). These bacteria are auxotrophic for some amino  
482 acids and must obtain them from the host in order to proliferate.

483

484 According to our results, L-serine availability contributes during the early infection phases  
485 to bacterial proliferation. A recent transposon mutagenesis highlights and supports the  
486 importance of *B. abortus* amino acid biosynthetic pathways during infection (67). Mutant  
487 strains in the genes coding for the enzymes involved in the anabolism of histidine and  
488 isoleucine, leucine and valine are attenuated at 24 hs p.i. in RAW 264.7 macrophages. At 2  
489 hs and 5 hs p.i., the mutants resemble L-serine auxotrophs, showing no differences with  
490 wild type in intracellular bacterial counts. Noticeably, although *serB* auxotrophic mutant is  
491 attenuated at 24 hs and 48 hs p.i., it is contained inside BCVs with replicative  
492 characteristics in HeLa cells, resembling wild type *B. abortus*. In HeLa cells, similar  
493 kinetics of LAMP-1 exclusion and calnexin recruitment to the BCVs suggests a  
494 dissociation between traffic events and replication capability for *serB*. However, in cells  
495 with proficient phagocytic activity such as J774A.1 macrophages, the biogenesis of the  
496 rBCV is impaired and the *serB* mutant resides in intracellular compartments positive for the  
497 late endosome/lysosome marker LAMP-1 and negative for the ER chaperone calnexin,  
498 where it is subjected to lysosomal degradation. Further studies are needed to address and  
499 characterize these observations.

500

501 The virulence attenuation of *B. abortus* caused by L-serine auxotrophy might be merely  
502 based on the requirement of this amino acid for protein biosynthesis. In addition, the  
503 virulence attenuation might be due to the role of L-serine as a precursor in  
504 phosphatidylethanolamine biosynthesis. Previous studies demonstrated that absence of PE  
505 in a *pssA* mutant altered cell surface properties, impaired intracellular survival and  
506 maturation of the replicative BCVs, and spleen colonization in mice (54). In the *pssA*  
507 mutant, the absence of PE was compensated by increasing the relative amount of the other  
508 lipids, in particular the ornithine lipid, as described here for *serB* auxotrophic mutant.  
509 However, absence of PE in *serB* cell envelope does not affect its resistance to acidic pH or  
510 to lysosome killing, suggesting that lack of L-serine is mainly responsible for the defect in  
511 intracellular replication.

512

513 In the mouse infection model, although attenuated in acute and chronic stages, *serB* mutant  
514 manages to persist in the spleen. This finding suggests that host tissues contain enough L-  
515 serine to support growth of this auxotrophic mutant. It is well established that macrophages  
516 can adopt two different immunological states: classical activated macrophages (CAM) with  
517 inflammatory cytokine production and bactericidal activity, and alternative activated  
518 macrophages (AAMs), which are less inflammatory and play relevant roles in homeostasis,  
519 allergic inflammation, wound healing and tissue repair (68, 69). During *in vivo* infection,  
520 *Brucella* is found within CAMs at early infection times, but survive and replicate  
521 preferentially in AAMs (70). In these cells, a metabolic shift to beta-oxidation of fatty acids  
522 induced by peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) increases intracellular  
523 glucose availability, which promotes intracellular survival and persistence of *Brucella* in  
524 AAMs (70). The fact that *serB* mutant is less attenuated in the late stages than in the early  
525 stages of mouse infection, could be related in part to the availability of amino acids (in  
526 particular L-serine) in each subtype of infected macrophages. Therefore, a better nutritional  
527 characterization of the microenvironment surrounding *B. abortus* in infected tissues would  
528 be useful to understand how bacteria adapt their metabolism to the different conditions  
529 found during the course of infection.

530

531

532 In the intracellular pathogens *Legionella pneumophila* and *Coxiella burnetti*, the host-cell  
533 L-serine is transported into the phagosome where the bacterial cell converts it into pyruvate  
534 to feed the TCA cycle, thus serving as the main source of carbon and energy (71).  
535 However, it seems not to be the case of *Brucella spp.*, which also require the activity of the  
536 TCA cycle for the intracellular stages, but they mainly depend on glutamic acid as an entry  
537 point into TCA (23, 72). In agreement with this, preliminary results from our group indicate  
538 that the mutant in the gene coding for the L-serine deaminase, involved in L-serine  
539 deamination to yield pyruvate, is not attenuated intracellularly like L-serine auxotrophic  
540 mutants.

541

542 In conclusion, although it is capable of incorporating L-serine from the extracellular milieu  
543 by a yet unidentified transporter, *B. abortus* depends on the biosynthesis of L-serine to  
544 sustain intracellular proliferation inside phagocytic and non-phagocytic cells. These  
545 findings highlight the L-serine biosynthetic pathway as an interesting target for the  
546 development of new drugs and/or strategies to combat brucellosis.

547 **AUTHOR AND CONTRIBUTIONS**

548 VR: data acquisition, data analysis, data interpretation, writing of the manuscript; MIM:  
549 data acquisition, data analysis, data interpretation, writing of the manuscript, revising of the  
550 manuscript; DC: data analysis, data interpretation, writing of the manuscript, revising of the  
551 manuscript, principle investigator.

552

553 **CONFLICT OF INTEREST STATEMENT**

554 The authors declare that the research was conducted in the absence of any financial or  
555 commercial relationships that would be construed as a potential conflict of interest.

556

557 **FUNDING**

558 This work was supported by PICT-2014-3359 and PICT-2016-1993 grants from Agencia  
559 Nacional de Promoción Científica y Tecnológica (ANPCyT), Argentina to D.J.C., and  
560 PICT-2017-0784 grant from ANPCyT to M.I.M.

561

562 **ACKNOWLEDGEMENTS**

563 We thank Francisco Guaimas for help in confocal microscopy image acquisition and  
564 processing. VR is a research fellow of Consejo Nacional de Investigaciones Científicas y  
565 Técnicas (CONICET), Argentina. D.J.C. and M.I.M are career investigators of CONICET.

566

567 **REFERENCES**

- 568 1. Moreno E. 2014. Retrospective and prospective perspectives on zoonotic  
569 brucellosis. *Front Microbiol* 5:1–18.
- 570 2. Celli J. 2019. The Intracellular Life Cycle of *Brucella* spp. *Microbiol Spectr* 7:1–11.
- 571 3. Salcedo SPSP, Marchesini MIMI, Lelouard H, Fugier E, Jolly G, Balor S, Muller A,  
572 Lapaque N, Demaria O, Alexopoulou L, Comerci DJDJ, Ugalde RARA, Pierre P, Gorvel J-  
573 PJ-P. 2008. *Brucella* control of dendritic cell maturation is dependent on the TIR-  
574 containing protein Btp1. *PLoS Pathog* 4:e21.
- 575 4. Atluri VL, Xavier MN, de Jong MF, den Hartigh AB, Tsolis RM. 2011. Interactions  
576 of the Human Pathogenic *Brucella* Species with Their Hosts. *Annu Rev Microbiol* 65:523–  
577 541.
- 578 5. Sedzicki J, Tschon T, Low SH, Willemart K, Goldie KN, Letesson J-J, Stahlberg H,  
579 Dehio C. 2018. 3D correlative electron microscopy reveals continuity of *Brucella* -  
580 containing vacuoles with the endoplasmic reticulum. *J Cell Sci* 131:jcs210799.
- 581 6. Celli J, Gorvel J-PP. 2004. Organelle robbery: *Brucella* interactions with the  
582 endoplasmic reticulum. *Curr Opin Microbiol* 7:93–97.
- 583 7. Starr T, Child R, Wehrly TD, Hansen B, Hwang S, López-Otin C, Virgin HW, Celli  
584 J. 2012. Selective subversion of autophagy complexes facilitates completion of the *Brucella*  
585 intracellular cycle. *Cell Host Microbe* 11:33–45.
- 586 8. Marchesini MI, Seijo SMM, Guaimas FF, Comerci DJ. 2016. A T4SS effector  
587 targets host cell alpha-enolase contributing to *Brucella abortus* intracellular lifestyle. *Front*  
588 *Cell Infect Microbiol* 6.
- 589 9. Marchesini MI, Herrmann CK, Salcedo SP, Gorvel J-P, Comerci DJ. 2011. In  
590 search of *Brucella abortus* type iv secretion substrates: Screening and identification of four  
591 proteins translocated into host cells through virB system. *Cell Microbiol* 13.
- 592 10. Miller CN, Smith EP, Cundiff JA, Knodler LA, Bailey Blackburn J, Lupashin V,  
593 Celli J. 2017. A *Brucella* Type IV Effector Targets the COG Tethering Complex to  
594 Remodel Host Secretory Traffic and Promote Intracellular Replication. *Cell Host Microbe*  
595 22:317-329.e7.
- 596 11. Salcedo SP, Marchesini MI, Degos C, Terwagne M, Bargen KV, Lepidi H,  
597 Herrmann CK, Santos Lacerda TL, Imbert PRC, Pierre P, Alexopoulou L, Letesson J-J,  
598 Comerci DJ, Gorvel J-P. 2013. BtpB, a novel *Brucella* TIR-containing effector protein with  
599 immune modulatory functions. *Front Cell Infect Microbiol* 4.

- 600 12. Lapaque N, Moriyon I, Moreno E, Gorvel J-P. 2005. Brucella lipopolysaccharide  
601 acts as a virulence factor. *Curr Opin Microbiol* 8:60–6.
- 602 13. Arellano-Reynoso B, Lapaque N, Salcedo S, Briones G, Ciocchini AE, Ugalde R,  
603 Moreno E, Moriyón I, Gorvel J-P. 2005. Cyclic beta-1,2-glucan is a Brucella virulence  
604 factor required for intracellular survival. *Nat Immunol* 6:618–25.
- 605 14. Guidolin LS, Arce-Gorvel V, Ciocchini AAE, Comerci DJ, Gorvel J-P. 2018.  
606 Cyclic  $\beta$ -Glucans at the bacteria-host cells interphase: one sugar ring to rule them all. *Cell*  
607 *Microbiol* 20:e12850.
- 608 15. Guzman-Verri C, Manterola L, Sola-Landa A, Parra A, Cloeckert A, Garin J,  
609 Gorvel J-P, Moriyon I, Moreno E, Lopez-Goni I. 2002. The two-component system  
610 BvrR/BvrS essential for *Brucella abortus* virulence regulates the expression of outer  
611 membrane proteins with counterparts in members of the Rhizobiaceae. *Proc Natl Acad Sci*  
612 *U S A* 99:12375–80.
- 613 16. Czibener C, Merwaiss F, Guaimas F, Del Giudice MG, Serantes DAR, Spera JM,  
614 Ugalde JE. 2016. BigA is a novel adhesin of *Brucella* that mediates adhesion to epithelial  
615 cells. *Cell Microbiol* 18:500–513.
- 616 17. Uzureau S, Godefroid M, Deschamps C, Lemaire J, De Bolle X, Letesson J-J. 2007.  
617 Mutations of the quorum sensing-dependent regulator VjbR lead to drastic surface  
618 modifications in *Brucella melitensis*. *J Bacteriol* 189:6035–47.
- 619 18. Arocena GM, Sieira R, Comerci DJ, Ugalde R a. 2010. Identification of the  
620 quorum-sensing target DNA sequence and N-Acyl homoserine lactone responsiveness of  
621 the *Brucella abortus* virB promoter. *J Bacteriol* 192:3434–40.
- 622 19. Byndloss MX, Tsolis RM. 2016. *Brucella* spp. Virulence Factors and Immunity.  
623 *Annu Rev Anim Biosci* 4:111–127.
- 624 20. Barbier T, Nicolas C, Letesson JJ. 2011. Brucella adaptation and survival at the  
625 crossroad of metabolism and virulence. *FEBS Lett* 585:2929–34.
- 626 21. de Lorenzo V. 2014. From the selfish gene to selfish metabolism: revisiting the  
627 central dogma. *Bioessays* 36:226–35.
- 628 22. Nataro JP. 2015. Pathogenesis--Thoughts from the Front Line. *Microbiol Spectr*  
629 3:17–26.
- 630 23. Beaufay F, De Bolle X, Hallez R. 2016. Metabolic control of cell division in  $\alpha$ -  
631 proteobacteria by a NAD-dependent glutamate dehydrogenase. *Commun Integr Biol*  
632 9:e1125052.



- 633 24. Köhler S, Michaux-Charachon S, Porte F, Ramuz M, Liautard J-PP. 2003. What is  
634 the nature of the replicative niche of a stealthy bug named *Brucella*? *Trends Microbiol*  
635 11:215–219.
- 636 25. Kohler S, Foulongne V, Ouahrani-Bettache S, Bourg G, Teyssier J, Ramuz M,  
637 Liautard J-P. 2002. The analysis of the intramacrophagic virulome of *Brucella suis*  
638 deciphers the environment encountered by the pathogen inside the macrophage host cell.  
639 *Proc Natl Acad Sci U S A* 99:15711–6.
- 640 26. Köhler S, Ouahrani-Bettache S, Layssac M, Teyssier J, Liautard JP. 1999.  
641 Constitutive and inducible expression of green fluorescent protein in *Brucella suis*. *Infect*  
642 *Immun* 67:6695–6697.
- 643 27. Foulongne V, Bourg G, Cazevieille C, Michaux-Charachon S, O’Callaghan D.  
644 2000. Identification of *Brucella suis* genes affecting intracellular survival in an in vitro  
645 human macrophage infection model by signature-tagged transposon mutagenesis. *Infect*  
646 *Immun* 68:1297–303.
- 647 28. Lestrade P, Delrue RM, Danese I, Didembourg C, Taminiau B, Mertens P, De Bolle  
648 X, Tibor A, Tang CM, Letesson JJ. 2000. Identification and characterization of in vivo  
649 attenuated mutants of *Brucella melitensis*. *Mol Microbiol* 38:543–51.
- 650 29. Wu Q, Pei J, Turse C, Ficht TA. 2006. Mariner mutagenesis of *Brucella melitensis*  
651 reveals genes with previously uncharacterized roles in virulence and survival. *BMC*  
652 *Microbiol* 6:102.
- 653 30. Hong PC, Tsolis RM, Ficht TA. 2000. Identification of Genes Required for Chronic  
654 Persistence of *Brucella abortus* in Mice. *Infect Immun* 68:4102–4107.
- 655 31. Eskra L, Canavessi A, Carey M, Splitter G. 2001. *Brucella abortus* genes identified  
656 following constitutive growth and macrophage infection. *Infect Immun* 69:7736–42.
- 657 32. Lamontagne J, Forest A, Marazzo E, Denis F, Butler H, Michaud J-F, Boucher L,  
658 Pedro I, Villeneuve A, Sitnikov D, Trudel K, Nassif N, Boudjelti D, Tomaki F, Chaves-  
659 Olarte E, Guzmán-Verri C, Brunet S, Côté-Martin A, Hunter J, Moreno E, Paramithiotis E.  
660 2009. Intracellular adaptation of *Brucella abortus*. *J Proteome Res* 8:1594–609.
- 661 33. Yu X-JJ, Walker DH, Liu Y, Zhang L. 2009. Amino acid biosynthesis deficiency in  
662 bacteria associated with human and animal hosts. *Infect Genet Evol* 9:514–517.
- 663 34. Essenberg RC, Sharma YK. 1993. Cloning of genes for proline and leucine  
664 biosynthesis from *Brucella abortus* by functional complementation in *Escherichia coli*. *J*  
665 *Gen Microbiol* 139:87–93.

- 666 35. Wattam AR, Inzana TJ, Williams KP, Mane SP, Shukla M, Almeida NF,  
667 Dickerman AW, Mason S, Moriyon I, O'Callaghan D, Whatmore AM, Sobral BW, Tiller R  
668 V., Hoffmaster AR, Frace MA, De Castro C, Molinaro A, Boyle SM, De BK, Setubal JC.  
669 2012. Comparative Genomics of Early-Diverging *Brucella* Strains Reveals a Novel  
670 Lipopolysaccharide Biosynthesis Pathway. *MBio* 3:e00388-12-e00388-12.
- 671 36. Barbier T, Zúñiga-Ripa A, Moussa S, Plovier H, Sternon JF, Lázaro-Antón L,  
672 Conde-Álvarez R, De Bolle X, Iriarte M, Moriyón I, Letesson JJ. 2018. *Brucella* central  
673 carbon metabolism: an update. *Crit Rev Microbiol* 44:182–211.
- 674 37. Köhler S, Porte F, Jubier-Maurin V, Ouahrani-Bettache S, Teyssier J, Liautard J-P.  
675 2002. The intramacrophagic environment of *Brucella suis* and bacterial response. *Vet*  
676 *Microbiol* 90:299–309.
- 677 38. Lestrade P, Dricot A, Delrue R, Lambert C, Martinelli V, Bolle X De, Letesson J,  
678 Tibor A. 2003. Attenuated Signature-Tagged Mutagenesis Mutants of *Brucella melitensis*  
679 Identified during the Acute Phase of Infection in Mice 71:7053–7060.
- 680 39. Locasale JW. 2013. Serine, glycine and one-carbon units: cancer metabolism in full  
681 circle. *Nat Rev Cancer* 13:572–83.
- 682 40. Bailey LB, Gregory JF. 1999. Folate Metabolism and Requirements. *J Nutr*  
683 129:779–782.
- 684 41. Schirch V, Hopkins S, Villar E, Angelaccio S. 1985. Serine  
685 hydroxymethyltransferase from *Escherichia coli*: purification and properties. *J Bacteriol*  
686 163:1–7.
- 687 42. Kahl-McDonagh MM, Ficht TA. 2006. Evaluation of Protection Afforded by  
688 *Brucella abortus* and *Brucella melitensis* Unmarked Deletion Mutants Exhibiting Different  
689 Rates of Clearance in BALB/c Mice. *Infect Immun* 74:4048–4057.
- 690 43. Schäfer A, Tauch A, Jäger W, Kalinowski J, Thierbach G, Pühler A. 1994. Small  
691 mobilizable multi-purpose cloning vectors derived from the *Escherichia coli* plasmids pK18  
692 and pK19: selection of defined deletions in the chromosome of *Corynebacterium*  
693 *glutamicum*. *Gene* 145:69–73.
- 694 44. Döhmer PH, Valguarnera E, Czibener C, Ugalde JE. 2014. Identification of a type  
695 IV secretion substrate of *Brucella abortus* that participates in the early stages of  
696 intracellular survival. *Cell Microbiol* 16:396–410.
- 697 45. Gerhardt P, Wilson JB. 1948. The Nutrition of *Brucellae*: Growth in Simple  
698 Chemically Defined Media. *J Bacteriol* 56:17–24.

- 699 46. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. 2005. Differential  
700 lysosomal proteolysis in antigen-presenting cells determines antigen fate. *Science*  
701 307:1630–4.
- 702 47. Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and purification.  
703 *Can J Biochem Physiol* 37:911–917.
- 704 48. DITTMER JC, LESTER RL. 1964. A simple, specific spray for the detection of  
705 phospholipids on thin-layer chromatograms. *J Lipid Res* 5:126–7.
- 706 49. Welsh CJ, Schmeichel K. 1991. Assays for investigations of signal transduction  
707 mechanisms involving phospholipase D: mass measurements of phosphatidate,  
708 phosphatidylethanol, and diacylglycerol in cultured cells. *Anal Biochem* 192:281–92.
- 709 50. Celli J, de Chastellier C, Franchini D-M, Pizarro-Cerda J, Moreno E, Gorvel J-P.  
710 2003. *Brucella abortus* evades macrophage killing via VirB-dependent sustained interactions with  
711 the endoplasmic reticulum. *J Exp Med* 198:545–56.
- 712 51. Comerci DJ, Martínez-Lorenzo MJ, Sieira R, Gorvel JP, Ugalde RA. 2001.  
713 Essential role of the VirB machinery in the maturation of the *Brucella abortus*-containing  
714 vacuole. *Cell Microbiol* 3:159–68.
- 715 52. Pizarro-Cerdá J, Moreno E, Sanguedolce V, Mege JL, Gorvel JP. 1998. Virulent  
716 *Brucella abortus* prevents lysosome fusion and is distributed within autophagosome-like  
717 compartments. *Infect Immun* 66:2387–92.
- 718 53. Starr T, Ng TW, Wehrly TD, Knodler LA, Celli J. 2008. *Brucella* intracellular  
719 replication requires trafficking through the late endosomal/lysosomal compartment. *Traffic*  
720 9:678–94.
- 721 54. Bukata L, Altabe S, de Mendoza D, Ugalde RA, Comerci DJ. 2008.  
722 Phosphatidylethanolamine Synthesis Is Required for Optimal Virulence of *Brucella*  
723 *abortus*. *J Bacteriol* 190:8197–8203.
- 724 55. Comerci DJ, Altabe S, de Mendoza D, Ugalde RA. 2006. *Brucella abortus*  
725 Synthesizes Phosphatidylcholine from Choline Provided by the Host. *J Bacteriol* 188:1929–  
726 1934.
- 727 56. Nelson DL, Cox MM, Lehninger AL. 2012. *Lehninger Principles of Biochemistry*.  
728 New York WH Free 1328.
- 729 57. Thompson JR, Bell JK, Bratt J, Grant GA, Banaszak LJ. 2005. Vmax regulation  
730 through domain and subunit changes. The active form of phosphoglycerate dehydrogenase.  
731 *Biochemistry* 44:5763–73.

- 732 58. Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR, Bloom BR. 2000.  
733 Attenuation of and Protection Induced by a Leucine Auxotroph of Mycobacterium  
734 tuberculosis. *Infect Immun* 68:2888–2898.
- 735 59. Smith DA, Parish T, Stoker NG, Bancroft GJ. 2001. Characterization of auxotrophic  
736 mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. *Infect*  
737 *Immun* 69:1142–50.
- 738 60. Pavelka MS, Chen B, Kelley CL, Collins FM, Jacobs WR. 2003. Vaccine efficacy  
739 of a lysine auxotroph of Mycobacterium tuberculosis. *Infect Immun* 71:4190–2.
- 740 61. Hoiseth SK, Stocker BA. 1981. Aromatic-dependent Salmonella typhimurium are  
741 non-virulent and effective as live vaccines. *Nature* 291:238–9.
- 742 62. Fields PI, Swanson R V, Haidaris CG, Heffron F. 1986. Mutants of Salmonella  
743 typhimurium that cannot survive within the macrophage are avirulent. *Proc Natl Acad Sci*  
744 *U S A* 83:5189–93.
- 745 63. O’Callaghan D, Maskell D, Liew FY, Easmon CS, Dougan G. 1988.  
746 Characterization of aromatic- and purine-dependent Salmonella typhimurium: attention,  
747 persistence, and ability to induce protective immunity in BALB/c mice. *Infect Immun*  
748 56:419–23.
- 749 64. Gesbert G, Ramond E, Rigard M, Frapy E, Dupuis M, Dubail I, Barel M, Henry T,  
750 Meibom K, Charbit A. 2014. Asparagine assimilation is critical for intracellular replication  
751 and dissemination of Francisella. *Cell Microbiol* 16:434–449.
- 752 65. Ramond E, Gesbert G, Guerrero IC, Chhuon C, Dupuis M, Rigard M, Henry T,  
753 Barel M, Charbit A. 2015. Importance of host cell arginine uptake in Francisella  
754 phagosomal escape and ribosomal protein amounts. *Mol Cell Proteomics* 14:870–81.
- 755 66. Price CTD, Al-Quadani T, Santic M, Rosenshine I, Abu Kwaik Y. 2011. Host  
756 proteasomal degradation generates amino acids essential for intracellular bacterial growth.  
757 *Science* (80- ) 334:1553–1557.
- 758 67. Sternon J-F, Godessart P, Gonçalves de Freitas R, Van der Henst M, Poncin K,  
759 Francis N, Willemart K, Christen M, Christen B, Letesson J-J, De Bolle X. 2018.  
760 Transposon Sequencing of *Brucella abortus* Uncovers Essential Genes for Growth *In Vitro*  
761 and Inside Macrophages. *Infect Immun* 86.
- 762 68. Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage  
763 activation. *Nat Rev Immunol* 8:958–969.
- 764 69. Gordon S, Martinez FO. 2010. Alternative Activation of Macrophages: Mechanism  
765 and Functions. *Immunity* 32:593–604.

- 766 70. Xavier MNN, Winter MGG, Spees AMM, den Hartigh AB, Nguyen K, Roux  
767 CMM, Silva TMAM a, Atluri VLL, Kerrinnes T, Keestra AMM, Monack DMM, Luciw  
768 PA a., Eigenheer RA a., Bäumlér AJJ, Santos RLL, Tsolis RMM, den Hartigh AB, Nguyen  
769 K, Roux CMM, Silva TMAM a, Atluri VLL, Kerrinnes T, Keestra AMM, Monack DMM,  
770 Luciw PA a., Eigenheer RA a., Bäumlér AJJ, Santos RLL, Tsolis RMM. 2013. PPAR $\gamma$ -  
771 mediated increase in glucose availability sustains chronic *Brucella abortus* infection in  
772 alternatively activated macrophages. *Cell Host Microbe* 14:159–70.
- 773 71. Best A, Abu Kwaik Y. 2019. Nutrition and Bipartite Metabolism of Intracellular  
774 Pathogens. *Trends Microbiol* 27:550–561.
- 775 72. Zúñiga-Ripa A, Barbier T, Conde-Álvarez R, Martínez-Gómez E, Palacios-Chaves  
776 L, Gil-Ramírez Y, Grilló MJ, Letesson JJ, Iriarte M, Moriyón I. 2014. *Brucella abortus*  
777 depends on pyruvate phosphate dikinase and malic enzyme but not on *fbp* and *glpX*  
778 fructose-1,6-bisphosphatases for full virulence in laboratory models. *J Bacteriol* 196:3045–  
779 3057.
- 780
- 781

782 **FIGURE LEGENDS**

783 **Figure 1. L-serine auxotrophy in *B. abortus*.** (A) Schematic representation of L-serine  
784 biosynthetic pathway in *B. abortus*. SerA-1/SerA-2: 3-phosphoglycerate dehydrogenase  
785 (EC 1.1.1.95), SerC: 3-phosphoserine aminotransferase (EC 2.6.1.52), SerB: phosphoserine  
786 phosphatase (EC 3.1.3.3). (B, D) Growth kinetics of *B. abortus* wild type (2308) and the  
787 indicated mutant strains in GW medium. Overnight cultures of bacteria grown in TSB were  
788 pelleted, washed, and resuspended in fresh GW medium in the presence or absence of 10  
789 mM L-serine. Growth was monitored by measuring the turbidity (OD at 600 nm) at  
790 different times. (C, E) Growth kinetics of *B. abortus* wild type (2308), auxotrophic mutants  
791 for L-serine and the complemented strains in GW medium without L-serine. Four  
792 independent experiments were performed in duplicates for each growth curve. Data are  
793 means  $\pm$ SD (error bars are within the size of the symbols) of a representative experiment  
794 performed in duplicate.

795

796 **Figure 2. L-serine biosynthesis is required for *B. abortus* intracellular replication.**  
797 Intracellular replication of the indicated strains in HeLa cells (A, C, E) and J774A.1  
798 macrophagic cells (B, D, F). CFU were enumerated at 4, 24 and 48 hours post infection  
799 (p.i.). When indicated, cell medium was supplemented with 10mM L-serine at the  
800 beginning of the infection. Data are means  $\pm$ SD of a representative experiment performed  
801 in triplicate. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ .

802

803 **Figure 3. L-serine supplementation rescues *B. abortus* serB intracellular replication**  
804 **during early infection phase.** Intracellular replication of the indicated strains in HeLa cells  
805 (A) and in JJ74A.1 macrophages (B). When indicated, medium was supplemented with 10  
806 mM L-serine at the indicated time p.i. Data are means  $\pm$ SD of a representative experiment  
807 performed in triplicate. \*\*\* $P < 0.001$ .

808

809 **Figure 4. Determination of the minimal concentration of L-serine necessary to rescue**  
810 **the *B. abortus* serB intracellular replication defect.** Intracellular replication of the  
811 indicated strains in HeLa cells. Cell medium was supplemented with the indicated

812 concentrations of L-serine at the beginning of the infection. Data are means  $\pm$ SD of a  
813 representative experiment performed in triplicate. \*\*\* $P < 0.001$ .

814

815 **Figure 5. *B. abortus serB* mutant fails to establish intracellular replication foci.**

816 Enumeration of intracellular bacteria in HeLa cells infected with the indicated strains at 24  
817 hours (A) and 48 hours post infection (B). When indicated, cell medium was supplemented  
818 with 10mM L-serine at the beginning of the infection. Data are means  $\pm$ SD of a  
819 representative experiment performed in duplicate. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ . (C)  
820 Representative confocal micrographs of HeLa cells infected with the indicated strains at 48  
821 h p.i. HeLa cells were labeled for calnexin (green) or *Brucella* (red) as described in  
822 Materials and Methods. Arrowheads indicate replication foci and insets show BCVs  
823 colocalizing with calnexin (arrows).

824

825 **Figure 6. *serB* is necessary for LAMP-1 exclusion from BCVs in phagocytic cells. (A)**

826 Quantification of LAMP-1 acquisition and exclusion by BCVs of wild type and *serB*  
827 mutant at 4, 24 and 48 hs post-infection in J774A.1 macrophages. Bars represent means  
828  $\pm$ SD of a representative experiment performed in duplicate. \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ . (B)  
829 Representative confocal micrographs of J774A.1 macrophages infected with the indicated  
830 strains at 48 h p.i. Cells were labeled for LAMP-1 (red) and *Brucella* (green) as described  
831 in Materials and Methods. Arrowheads indicate LAMP-1 and *Brucella* colocalization for  
832 *serB* mutant and smaller arrowheads show puncta/dots suggestive of bacterial lysosomal  
833 degradation.

834

835 **Figure 7. Phosphatidylethanolamine (PE) synthesis is abrogated in *B. abortus serB***

836 **mutant. (A)** Schematic representation of PE biosynthetic pathway in *B. abortus*. PssA:  
837 Phosphatidylserine synthase; Psd: Phosphatidylserine decarboxylase. *B. abortus* strains  
838 were grown in minimum medium with choline, and 10mM L-serine was added to the  
839 medium when indicated. Total lipids were isolated and separated by thin layer  
840 chromatography analysis. Lipid spots corresponding to phosphatidylglycerol (PG),  
841 ornithine lipid (OL), phosphatidylethanolamine (PE), cardiolipin (CL) and

842 phosphatidylcholine (PC) are indicated. Total lipids were visualized by sulfuric acid  
843 charring (B) and aminolipids were visualized by ninhydrin staining (C).

844

845 **Figure 8. *B. abortus serB* mutant is defective for mice spleen colonization.** BALB/c  
846 mice were inoculated intraperitoneally with *B. abortus* wild type, *serB* mutant, or the  
847 complemented strain, as indicated in Materials and Methods. Bacteria were recovered from  
848 spleens at 7, 15 and 30 days post infection. Individual CFU values are plotted and  
849 horizontal dashed lines represent the median bacterial load for each treatment group.  
850 Statistical significance was determined by one-way ANOVA \*\*P <0.01; \*\*\* P <0.001.

851

852



Figure 1




Figure 2




Figure 3




Figure 4




Figure 5





Figure 6

A



B




Figure 7




Figure 8

